Cheng Xi, Cai Shu-Mo, Li Zi-Ting, Tang Mei-Qin, Xue Mu-Quan, Zang Rong-Yu
Department of Gynecological Oncology, Cancer Hospital, Fudan University, Shanghai, PR China.
Ai Zheng. 2003 Nov;22(11):1219-23.
BACKGROUND & OBJECTIVE: Pelvic lymph node metastasis was the important prognostic factor for the patients with cervical carcinoma. However, the relationship among the number of positive nodes, site of metastatic nodes, adjuvant therapy, and the prognosis were unknown. The purpose of this study was to investigate the variables that could predict the prognosis of the patients with stage Ib-IIb node-positive cervical carcinoma.
Sixty-six patients with stage Ib-IIb cervical carcinoma who underwent radical hysterectomy and pelvic lymphadenectomy were analyzed retrospectively. Potential prognostic variables were studied by Cox proportional hazard model.
The 5-year survival rate of the patients with pelvic lymph node metastasis was 40.7%. Cox proportional hazard model analysis showed cellular differentiation, number of positive nodes, and adjuvant therapy were the important prognostic factors (P< 0.05). The 5-year survival rate of patients with one positive node (56.5%) was higher than that (36.4%) of those with two or more positive nodes (P< 0.05). The former's distant metastatic rate (5.9%) was lower than the latter's (32.7%) (P=0.05). However, there was no difference of pelvic recurrence between them (P >0.05). The 5-year survival rate of the patients who had no adjuvant therapy (12.6%) was much lower than that (53.7%) of those with adjuvant therapy (P< 0.05). However, the differences of the effects among adjuvant radiotherapy, chemotherapy, and chemoradiotherapy were not obvious (P >0.05).
The prognosis of patients with stage Ib-IIb node-positive cervical carcinoma who underwent radical surgery was poor. Adjuvant therapy can improve the survival rate, decrease the pelvic recurrence and distant metastasis.
盆腔淋巴结转移是宫颈癌患者重要的预后因素。然而,阳性淋巴结数目、转移淋巴结部位、辅助治疗与预后之间的关系尚不清楚。本研究旨在探讨可预测Ib-IIb期淋巴结阳性宫颈癌患者预后的变量。
回顾性分析66例行根治性子宫切除术及盆腔淋巴结清扫术的Ib-IIb期宫颈癌患者。采用Cox比例风险模型研究潜在的预后变量。
盆腔淋巴结转移患者的5年生存率为40.7%。Cox比例风险模型分析显示,细胞分化程度、阳性淋巴结数目及辅助治疗是重要的预后因素(P<0.05)。单个阳性淋巴结患者的5年生存率(56.5%)高于两个或更多阳性淋巴结患者(36.4%)(P<0.)。前者的远处转移率(5.9%)低于后者(32.7%)(P=0.05)。然而,两者之间盆腔复发无差异(P>0.05)。未接受辅助治疗患者的5年生存率(12.6%)远低于接受辅助治疗患者(53.7%)(P<0.05)。然而,辅助放疗、化疗及放化疗之间的疗效差异不明显(P>0.05)。
行根治性手术的Ib-IIb期淋巴结阳性宫颈癌患者预后较差。辅助治疗可提高生存率,降低盆腔复发及远处转移。